Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative

Publication Date: January 9, 2023
Last Updated: May 10, 2023

Treatment

New Recommendation from 2023 Guideline Rapid Recommendation Update

Patients with hormone receptor-positive HER2-negative metastatic breast cancer who are refractory to endocrine therapy and have received at least 2 prior lines of chemotherapy for metastatic disease may be offered sacituzumab govitecan. (Quality of Evidence - Medium) ( EB , , B , S )
3336

Overview

Title

Chemotherapy and Targeted Therapy for Patients With Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer That is Either Endocrine-Pretreated or Hormone Receptor–Negative

Authoring Organization

American Society of Clinical Oncology